JP2007523177A5 - - Google Patents

Download PDF

Info

Publication number
JP2007523177A5
JP2007523177A5 JP2006554220A JP2006554220A JP2007523177A5 JP 2007523177 A5 JP2007523177 A5 JP 2007523177A5 JP 2006554220 A JP2006554220 A JP 2006554220A JP 2006554220 A JP2006554220 A JP 2006554220A JP 2007523177 A5 JP2007523177 A5 JP 2007523177A5
Authority
JP
Japan
Prior art keywords
compound
fluorophenyl
phenyl
tumor
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006554220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523177A (ja
JP4934432B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/005151 external-priority patent/WO2005080352A2/en
Publication of JP2007523177A publication Critical patent/JP2007523177A/ja
Publication of JP2007523177A5 publication Critical patent/JP2007523177A5/ja
Application granted granted Critical
Publication of JP4934432B2 publication Critical patent/JP4934432B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006554220A 2004-02-19 2005-02-17 キナゾリン誘導体およびキナゾリン誘導体の治療への使用 Expired - Fee Related JP4934432B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54548704P 2004-02-19 2004-02-19
US60/545,487 2004-02-19
PCT/US2005/005151 WO2005080352A2 (en) 2004-02-19 2005-02-17 Quinazoline derivatives and therapeutic use thereof

Publications (3)

Publication Number Publication Date
JP2007523177A JP2007523177A (ja) 2007-08-16
JP2007523177A5 true JP2007523177A5 (enExample) 2008-03-13
JP4934432B2 JP4934432B2 (ja) 2012-05-16

Family

ID=34886161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006554220A Expired - Fee Related JP4934432B2 (ja) 2004-02-19 2005-02-17 キナゾリン誘導体およびキナゾリン誘導体の治療への使用

Country Status (11)

Country Link
US (2) US7388014B2 (enExample)
EP (2) EP2650286A1 (enExample)
JP (1) JP4934432B2 (enExample)
KR (1) KR100942865B1 (enExample)
CN (1) CN1956966B (enExample)
AU (1) AU2005214373B2 (enExample)
BR (1) BRPI0507903A (enExample)
CA (1) CA2557433C (enExample)
ES (1) ES2554330T3 (enExample)
MX (1) MXPA06009475A (enExample)
WO (1) WO2005080352A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2567133T3 (es) * 2005-06-23 2016-04-20 Array Biopharma, Inc. Proceso para preparar compuestos de benzoimidazol
EP2021019A4 (en) * 2006-05-15 2009-12-09 Senex Biotechnology Inc IDENTIFICATION OF CDKI PATH HAZARD
AU2008236994A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
CN101120945B (zh) * 2007-07-30 2010-11-24 浙江大学 8-芳胺基-3H-咪唑[4,5-g]喹唑啉类衍生物的用途
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
CA2805148C (en) * 2010-07-14 2016-01-19 Zhejiang Beta Pharma Inc. Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors
SG11201401343YA (en) * 2011-09-13 2014-08-28 Igor Roninson TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
CN103086984A (zh) * 2011-11-03 2013-05-08 南京大学 一类4-苯氨基喹唑啉类衍生物及其制备方法与用途
JP2015512891A (ja) 2012-03-13 2015-04-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
CN102659692B (zh) 2012-05-04 2014-04-09 郑州泰基鸿诺药物科技有限公司 双联厄洛替尼及其制备方法
CN102875570B (zh) * 2012-10-23 2015-11-04 浙江大学 喹唑啉衍生物及其制备方法和用途
CN105407894A (zh) 2013-03-14 2016-03-16 康威基内有限公司 用于抑制含布罗莫结构域的蛋白质的方法和组合物
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
EP3046915A1 (en) 2013-09-16 2016-07-27 Basf Se Fungicidal pyrimidine compounds
MX2016003522A (es) * 2013-09-19 2016-12-15 Pf Medicament Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
CN104926798B (zh) * 2014-03-21 2019-06-18 江苏豪森药业集团有限公司 阿法替尼中间体的高纯度制备方法
US10508106B2 (en) * 2015-11-25 2019-12-17 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
KR102602820B1 (ko) * 2017-01-30 2023-11-15 시오노기세이야쿠가부시키가이샤 퀴나졸린 유도체를 함유하는 고형 제제
JP7659269B2 (ja) * 2018-12-21 2025-04-09 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック 抗酸菌症治療のためのｂｄオキシダーゼ阻害剤の発見
US12497395B2 (en) 2019-04-24 2025-12-16 Convergene, Llc Small molecule bromodomain inhibitors and uses therof
KR102397359B1 (ko) * 2019-09-30 2022-05-11 한국화학연구원 4-아미노-퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
WO2021130731A1 (en) * 2019-12-27 2021-07-01 Lupin Limited Substituted tricyclic compounds
TWI807787B (zh) * 2021-04-19 2023-07-01 大陸商昆藥集團股份有限公司 苯並嘧啶三環衍生物及製備方法和應用
CN116444443B (zh) * 2023-03-15 2025-09-05 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种苯甲酰-喹唑啉酮衍生物及其制备方法与应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH492395A (de) 1966-04-26 1970-06-30 Sandoz Ag Mittel zur Bekämpfung von Pflanzenschädlingen und Verwendung des Mittels
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
IL89028A0 (en) * 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1996029331A1 (de) * 1995-03-20 1996-09-26 Dr. Karl Thomae Gmbh Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE69522717T2 (de) 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
DE69734513T2 (de) * 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
US6127541A (en) 1996-08-30 2000-10-03 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
AU779695B2 (en) 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
DE10042060A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them

Similar Documents

Publication Publication Date Title
JP2007523177A5 (enExample)
Hesham et al. Chimeric HDAC inhibitors: Comprehensive review on the HDAC‐based strategies developed to combat cancer
JP6021805B2 (ja) 腫瘍治療剤
RU2425041C2 (ru) Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
JP4934432B2 (ja) キナゾリン誘導体およびキナゾリン誘導体の治療への使用
JP2010528026A5 (enExample)
JP2019517487A5 (enExample)
TWI594986B (zh) Antineoplastic agent effect enhancer
JP2018510851A5 (enExample)
CN114430741A (zh) Egfr抑制剂、组合物及其制备方法
JP2013507415A5 (enExample)
JP2005534626A5 (enExample)
JP2013525458A5 (enExample)
RU2007140734A (ru) Замещенные гетероциклы и их применение в качестве ингибиторов chki, pdki и pak
JP2009541223A5 (enExample)
JP2007515413A5 (enExample)
JP2004511512A5 (enExample)
JP2004525908A5 (enExample)
JP2007517807A5 (enExample)
JP2003507342A (ja) 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物
JP2015522607A5 (enExample)
JP2009534418A5 (enExample)
JP2004525184A5 (enExample)
JP2004530655A5 (enExample)
RU2483064C2 (ru) Твердые формы ингибитора raf-киназы